Mylan Inks $96.5M Pay-For-Delay Deal With Cephalon Buyers

By Suevon Lee (February 3, 2017, 10:21 PM EST) -- Mylan Pharmaceuticals Inc. has agreed to pay $96.5 million to settle with direct purchasers in pay-for-delay litigation over Cephalon's narcolepsy drug Provigil, according to a court filing in Pennsylvania federal court.

The Pennsylvania-based drugmaker's proposed deal with direct purchasers including King Drug Co. of Florence Inc., Burlington Drug Co., Meijer Inc. and others comes in a decade-old suit against several companies alleging unlawful, pay-for-delay conduct involving the sleep disorder prescription drug.

The suit accused Mylan and Ranbaxy Laboratories of inking pay-for-delay deals with Cephalon Inc. to keep generic versions of the drug off the market. Consumers, retailers and others alleged they...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!